Head-to-head evidence
elecoglipron vs TE-8105
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
elecoglipron
Developed by AstraZeneca
NCT06579092 · Phase 2 · completed
This randomised, triple-blind, placebo-controlled trial in 310 adults living with obesity or overweight reported a 10.5% reduction in body weight on elecoglipron 75 mg against 0.6% on placebo at 26 weeks. Percent weight change is the measure regulators accept as the primary efficacy endpoint in obesity.
Next expected readout: April 2028 · NCT07775404 (registry estimate)
TE-8105
Developed by Immunwork
NCT06471530 · Phase 1/2 · completed
This was an open-label, non-randomized, dose-escalation study with no placebo or control group, so it cannot show whether any effect is attributable to the drug itself. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: elecoglipron's landscape · TE-8105's landscape